Comprehensive Digestive Stool Analysis (CDSA)

The Comprehensive Digestive Stool Analysis | Genova Diagnostics
This test evaluates digestion and absorption, bacterial balance and metabolism, yeast and immune status for patients with irritable bowel syndrome, indigestion, malabsorption, and other GI-related problems. Additionally, Genova offers a parasitology component with the CDSA test that evaluates for parasites using microscopic examination and EIA testing

Think of your body as a finely tuned engine, and food is its fuel. If you aren't completely digesting foods and absorbing nutrients, you're not adequately fueling your body. The lack of adequate fuel–or the inability to use it properly–can lead to a variety of health problems.

Poor digestion or imbalances in your intestinal flora can result in many illnesses, from annoying gastrointestinal complaints such as chronic constipation and abdominal pain to more serious illnesses which may appear to be unrelated to digestion, such as asthma or migraines.

Your clinician knows the importance of evaluating your gastrointestinal health. One important tool to aid in this diagnosis is the Comprehensive Digestive Stool Analysis.

The CDSA is a group of 25 tests performed on a stool sample, revealing valuable information about your gastrointestinal health.

The CDSA evaluates:

• Digestion of food molecules and absorption of nutrients.
• The presence of hidden yeast or bacterial infections.
• Intestinal flora balance.
• Intestinal immune function.
• Dietary fiber intake.

The CDSA is comprised of the following clinically useful panels:

• Digestion Markers: An indirect evaluation of digestive function, providing insight into adequate digestive enzyme production and maldigestion. Markers include Chymotrypsin, Putrefactive Short Chain Fatty Acids (SCFAs), Meat Fibers and Vegetable Fibers.

• Absorption Markers: Elevated levels of the listed fatty acids may indicate maldigestion, malabsorption, altered transit time, and small bowel bacterial overgrowth. Markers include Long Chain Fatty Acids, Phospholipids, Cholesterol, Triglycerides and Total Fecal Fat.

• Metabolic Markers: These markers identify imbalances that are associated with increased toxic burden, small bowel bacterial overgrowth or severe inflammation. Abnormal levels are associated primarily with intestinal conditions, including potential risk for colorectal cancer. Markers include Beneficial SCFAs, n-Butyrate, Beta-Glucuronidase†, pH, Fecal Lactoferrin, Macroscopic exam, and Occult blood.

• Microbiology Markers: Provides quantitative measures of the beneficial flora Lactobacillis and bifidobacterium as well as additional aerobic flora as they present in culture. These include strict pathogenic bacteria and potentially pathogenic bacteria and yeast.

• Optional Parasitology: (EIA and microscopic evaluation) This evaluation demonstrates the highest documented recovery rates available (22% positivity rate). It quantifies all ova and parasites identified. Microscopic evaluation for yeast and blood cells is included.

Optional Ova and Parasite Test